This has led to the discovery of several promising biomarkers reflecting the different sites of pathology in ALS, such as NfL, which indicates motor neuron degeneration and is currently the biomarker of choice in ALS studies given its abundance and correlation with clinical outcomes (15). This evidence concerns the gene NEFL and amyotrophic lateral sclerosis.